Inj, nogapendekin pmln, 1mcg
Products billed under this code include Anktiva.
Payment limit per 1 MCG, by effective quarter, 1Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Anktiva.
Payment limit per 1 MCG, by effective quarter, 1Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Anktiva | Altor BioScience, LLC | 81481-0803-01 | 400 | $37,655.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $94.139 | −$0.167 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted September 17, 2026 |
| 3Q26 | $94.306 | −$0.292 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted September 15, 2026 |
| 2Q26 | $94.598 | −$0.13 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted September 15, 2026 |
| 1Q26 | $94.728 | +$0.066 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted September 15, 2026 |
| 4Q25 | $94.662 | +$0.547 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted September 8, 2026 |
| 3Q25 | $94.115 | −$0.466 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted March 10, 2026 |
| 2Q25 | $94.581 | −$0.289 | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted March 10, 2026 |
| 1Q25 | $94.87 | – | 1 MCG | Inj, nogapendekin pmln, 1mcg | v1, posted December 19, 2025 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.